Legacy Private Trust Co. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,379 shares of the company’s stock after selling 1,519 shares during the period. Legacy Private Trust Co.’s holdings in Johnson & Johnson were worth $5,738,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in JNJ. Lenox Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after acquiring an additional 841 shares in the last quarter. Ullmann Financial Group Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $186,000. Taylor Wealth Management Partners grew its stake in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after acquiring an additional 250 shares in the last quarter. Finally, Hutchens Investment Management Inc bought a new position in shares of Johnson & Johnson in the first quarter valued at $204,000. Institutional investors and hedge funds own 65.89% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/legacy-private-trust-co-sells-1519-shares-of-johnson-johnson-jnj.html.
Several equities analysts recently weighed in on JNJ shares. Morgan Stanley raised their target price on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, July 5th. Cowen and Company reaffirmed an “outperform” rating and set a $155.00 price objective (up from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS AG reaffirmed a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research report on Thursday, August 31st. BidaskClub cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $143.70.
Shares of Johnson & Johnson (JNJ) traded up 0.2527% during trading on Friday, reaching $142.1683. The company’s stock had a trading volume of 1,865,993 shares. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $144.35. The stock’s 50 day moving average price is $134.68 and its 200-day moving average price is $131.18. The stock has a market cap of $381.58 billion, a price-to-earnings ratio of 24.7249 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.68 earnings per share. Equities analysts anticipate that Johnson & Johnson will post $7.28 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.